Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Abiogen gets Effrx's Binosto (alendronate sodium), an effervescent tablet for the treatment of osteoporosis. It will allow Abiogen to continue developing on Effrx's bisphosphonates family of molecules that in the area of osteoarticular metabolism.
Lead Product(s): Alendronate Sodium
Therapeutic Area: Musculoskeletal Product Name: Binosto
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: EffRx Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 29, 2023